KITE-363 Phase 1 Study Initiated for Autoimmune Neurologic Diseases
Kite, Gilead Company, is conducting Phase 1 study to evaluate the safety and efficacy of KITE-363 in patients with relapsed/refractory autoimmune neurologic diseases.
Company
Pharmaceutical intelligence for Kite Pharma with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.